Summary & Overview
HCPCS G8464: Prostate Cancer—Not Eligible for Adjuvant Hormonal Therapy
HCPCS Level II code G8464 documents a clinician’s determination that a prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy because of low or intermediate recurrence risk or because recurrence risk was not determined. As a status/prognostic claim descriptor, this code matters nationally for care coordination, quality measurement, and payer adjudication where therapy eligibility influences coverage and follow-up planning. Key national payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what the code denotes clinically, where it is typically used (outpatient oncology or urology clinics), and how it is applied in administrative and quality documentation. The publication provides benchmarks, policy context, and clinical considerations tied to documentation of eligibility decisions, highlighting implications for coverage pathways and downstream treatment planning. Data not available in the input is noted where applicable for specific payer policies, modifiers, taxonomies, ICD-10 linkage, and related billing lines.
Billing Code Overview
HCPCS Level II code G8464 documents that a clinician has recorded the patient with prostate cancer as not an eligible candidate for adjuvant hormonal therapy due to either a low or intermediate risk of recurrence or because the risk of recurrence was not determined. This code captures clinical eligibility determination rather than the delivery of therapy.
-
Service type: Clinical eligibility assessment related to adjuvant hormonal therapy decision-making
-
Typical site of service: Oncology clinic or outpatient urology/oncology practice setting
Clinical & Coding Specifications
Clinical Context
A 68-year-old man with a recent diagnosis of localized prostate adenocarcinoma presents for postoperative or post-diagnostic treatment planning. The treating clinician (urologist or radiation oncologist) documents that the patient is not an eligible candidate for adjuvant androgen deprivation therapy (ADT) because the tumor is low- or intermediate-risk for recurrence, or because risk of recurrence cannot be determined due to incomplete staging information or patient comorbidities. Typical clinical workflow includes review of pathology (Gleason score), PSA trajectory, imaging results, and patient comorbidity assessment. The clinician documents the decision and the rationale in the medical record during an outpatient visit; this supports billing of G8464 to indicate that adjuvant hormonal therapy is not appropriate or is deferred. Typical site of service is an outpatient clinic (urology or radiation oncology office) or hospital outpatient department where treatment planning and shared decision-making occur. Typical patient scenario: an elderly patient with PSA 6.5 ng/mL, Gleason 3+4=7 on biopsy, no adverse pathologic features after prostatectomy, and significant cardiovascular comorbidity that increases ADT risk — clinician records that adjuvant hormonal therapy is not indicated given low–intermediate recurrence risk and comorbidities.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable E/M service by the same physician on the day of a procedure |